Hans-Joachim Anders

Dec 8, 2024 | nature.com | Hans-Joachim Anders

Correction to: Nature Reviews Rheumatology https://doi.org/10.1038/s41584-024-01158-w, published online 24 September 2024. In the version of the article initially published, in Fig. 2b, the label “IIanalumab” was incorrect and has now been amended to “Ianalumab”. Additionally, the target of Ianalumab was incorrectly shown to be BAFF-R/BCMA/TACI, and the labels “Epratuzumab” and “Anifrolumab” originally both read “IIanalumab”.

Sep 30, 2024 | ard.bmj.com | Andreas Kronbichler |Hans-Joachim Anders |Eleni Frangou |Safak Mirioglu

Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al Free Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Sep 23, 2024 | nature.com | Hans-Joachim Anders

AbstractLupus nephritis is a common complication of systemic lupus erythematosus (SLE) and a determinant of overall morbidity and mortality, as lupus nephritis-related chronic kidney disease (CKD) drives cardiovascular disease and secondary immunodeficiency.

May 15, 2024 | ard.bmj.com | Maria Soler |Conxita Jacobs Cachá |Hans-Joachim Anders |Policlinic IV

Correspondence on: ‘SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy’ by Zhao et al Free Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Apr 5, 2024 | ard.bmj.com | Andreas Kronbichler |Hans-Joachim Anders |Eleni Frangou |Safak Mirioglu

Lupus Erythematosus, SystemicLupus NephritisMortalityThe recently published European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) (2023 update)1 recognise the major achievements in treating lupus nephritis (LN).